• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV Tat 结构域以基因和侧翼序列依赖的方式改善了人类半乳糖脑苷脂酶的交叉校正。

HIV Tat Domain Improves Cross-correction of Human Galactocerebrosidase in a Gene- and Flanking Sequence-dependent Manner.

机构信息

Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas, USA.

出版信息

Mol Ther Nucleic Acids. 2013 Oct 22;2(10):e130. doi: 10.1038/mtna.2013.57.

DOI:10.1038/mtna.2013.57
PMID:24150577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4027426/
Abstract

Krabbe disease is a devastating neurodegenerative lysosomal storage disorder caused by a deficiency of β-galactocerebrosidase (GALC). Gene therapy is a promising therapeutic approach for Krabbe disease. As the human brain is large and it is difficult to achieve global gene transduction, the efficacy of cross-correction is a critical determinant of the outcome of gene therapy for this disease. We investigated whether HIV Tat protein transduction domain (PTD) can improve the cross-correction of GALC. Tat-PTD significantly increased (~6-fold) cross-correction of GALC through enhanced secretion and uptake in a cell-culture model system. The effects of Tat-PTD were gene and flanking amino acids dependent. Tat-fusion increased the secretion of α-galactosidase A (α-gal A), but this did not improve its cross-correction. Tat-fusion did not change either secretion or uptake of β-glucocerebrosidase (GC). Tat-PTD increased GALC protein synthesis, abolished reactivity of GC to the 8E4 antibody, and likely reduced mannose phosphorylation in all these lysosomal enzymes. This study demonstrated that Tat-PTD can be useful for increasing cross-correction efficiency of lysosomal enzymes. However, Tat-PTD is not a mere adhesive motif but possesses a variety of biological functions. Therefore, the potential beneficial effect of Tat-PTD should be assessed individually on each lysosomal enzyme.Molecular Therapy-Nucleic Acids (2013) 2, e130; doi:10.1038/mtna.2013.57; published online 22 October 2013.

摘要

克拉伯病是一种破坏性的神经退行性溶酶体贮积症,由β-半乳糖脑苷脂酶(GALC)缺乏引起。基因治疗是克拉伯病的一种有前途的治疗方法。由于人脑较大,难以实现全局基因转导,因此交叉校正的效果是该疾病基因治疗结果的关键决定因素。我们研究了 HIV Tat 蛋白转导结构域(PTD)是否可以改善 GALC 的交叉校正。在细胞培养模型系统中,Tat-PTD 通过增强分泌和摄取,显著增加了 GALC 的交叉校正(~6 倍)。Tat-PTD 的作用取决于基因和侧翼氨基酸。Tat 融合增加了α-半乳糖苷酶 A(α-gal A)的分泌,但这并没有改善其交叉校正。Tat 融合既没有改变β-葡糖苷脑苷脂酶(GC)的分泌也没有改变其摄取。Tat-PTD 增加了 GALC 蛋白合成,使 GC 对 8E4 抗体失去反应性,并可能降低所有这些溶酶体酶中的甘露糖磷酸化。这项研究表明,Tat-PTD 可用于提高溶酶体酶的交叉校正效率。然而,Tat-PTD 不仅仅是一个粘附基序,而是具有多种生物学功能。因此,应该单独评估 Tat-PTD 对每种溶酶体酶的潜在有益作用。分子治疗-核酸(2013 年)2,e130;doi:10.1038/mtna.2013.57;2013 年 10 月 22 日在线发表。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/7805607fbf48/mtna201357f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/21091994c01e/mtna201357f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/4fcbdc9dd40d/mtna201357f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/d480ee212f21/mtna201357f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/e083806ea003/mtna201357f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/7805607fbf48/mtna201357f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/21091994c01e/mtna201357f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/4fcbdc9dd40d/mtna201357f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/d480ee212f21/mtna201357f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/e083806ea003/mtna201357f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b19b/4027426/7805607fbf48/mtna201357f5.jpg

相似文献

1
HIV Tat Domain Improves Cross-correction of Human Galactocerebrosidase in a Gene- and Flanking Sequence-dependent Manner.HIV Tat 结构域以基因和侧翼序列依赖的方式改善了人类半乳糖脑苷脂酶的交叉校正。
Mol Ther Nucleic Acids. 2013 Oct 22;2(10):e130. doi: 10.1038/mtna.2013.57.
2
Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV Tat protein transduction domain.携带HIV Tat蛋白转导结构域的半乳糖脑苷脂酶的细胞摄取及溶酶体递送
J Neurochem. 2008 Feb;104(4):1055-64. doi: 10.1111/j.1471-4159.2007.05030.x. Epub 2007 Nov 6.
3
Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy.将Tat蛋白转导结构域基因掺入腺病毒5型纤维中可增强基因传递效率。
Virol J. 2007 Oct 24;4:103. doi: 10.1186/1743-422X-4-103.
4
Delivery of TAT/PTD-fused proteins/peptides to islets via pancreatic duct.通过胰管将TAT/PTD融合蛋白/肽递送至胰岛。
Cell Transplant. 2005;14(5):241-8. doi: 10.3727/000000005783983016.
5
Targeting of HIV-1 Tat traffic and function by transduction-competent single chain antibodies.具有转导能力的单链抗体对HIV-1反式激活因子运输和功能的靶向作用
Vaccine. 2006 Apr 12;24(16):3127-36. doi: 10.1016/j.vaccine.2006.01.055. Epub 2006 Feb 9.
6
The kinetics and tissue distribution of protein transduction in mice.小鼠体内蛋白质转导的动力学及组织分布
Eur J Pharm Sci. 2006 Mar;27(4):311-9. doi: 10.1016/j.ejps.2005.10.011. Epub 2006 Jan 11.
7
Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells.对1型人类免疫缺陷病毒Tat蛋白转导结构域的突变分析,该结构域是将外源蛋白递送至哺乳动物细胞所必需的。
J Gen Virol. 2002 May;83(Pt 5):1173-1181. doi: 10.1099/0022-1317-83-5-1173.
8
Fluorimetric assay with a novel substrate for quantification of galactocerebrosidase activity in dried blood spot specimens.一种使用新型底物的荧光测定法,用于定量干血斑样本中的半乳糖脑苷脂酶活性。
Pract Lab Med. 2019 Oct 16;18:e00141. doi: 10.1016/j.plabm.2019.e00141. eCollection 2020 Jan.
9
Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction.糖胺聚糖在 TAT 蛋白转导结构域介导的细胞转导中的修正作用。
J Biol Chem. 2010 Jan 8;285(2):1500-7. doi: 10.1074/jbc.M109.021964. Epub 2009 Oct 26.
10
Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.六邻体 Tat 蛋白转导结构域修饰的腺病毒在实验性神经母细胞瘤和神经内分泌肿瘤中表现出增强的治疗效果。
J Virol. 2011 Dec;85(24):13114-23. doi: 10.1128/JVI.05759-11. Epub 2011 Sep 28.

引用本文的文献

1
Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neurons.利用工程化的弓形虫分泌系统将多种大型治疗性蛋白递送至神经元细胞内。
Nat Microbiol. 2024 Aug;9(8):2051-2072. doi: 10.1038/s41564-024-01750-6. Epub 2024 Jul 29.
2
Krabbe Disease: Prospects of Finding a Cure Using AAV Gene Therapy.克拉伯病:使用腺相关病毒基因疗法寻找治愈方法的前景。
Front Med (Lausanne). 2021 Nov 11;8:760236. doi: 10.3389/fmed.2021.760236. eCollection 2021.
3
Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease.

本文引用的文献

1
Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease.AAVrh10 介导的基因治疗可延长克拉伯病小鼠模型的正常寿命。
Mol Ther. 2012 Nov;20(11):2031-42. doi: 10.1038/mt.2012.153. Epub 2012 Jul 31.
2
Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction.甘露糖-6-磷酸途径:对其在溶酶体功能和功能障碍中的作用的综述。
Mol Genet Metab. 2012 Apr;105(4):542-50. doi: 10.1016/j.ymgme.2011.12.012. Epub 2011 Dec 23.
3
Determinants of translation efficiency and accuracy.翻译效率和准确性的决定因素。
脑靶向载酶纳米颗粒:克拉伯病酶替代治疗突破血脑屏障。
Sci Adv. 2019 Nov 20;5(11):eaax7462. doi: 10.1126/sciadv.aax7462. eCollection 2019 Nov.
4
Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.克拉伯病的生物化学、细胞生物学、病理学及治疗学方面
J Neurosci Res. 2016 Nov;94(11):990-1006. doi: 10.1002/jnr.23873.
Mol Syst Biol. 2011 Apr 12;7:481. doi: 10.1038/msb.2011.14.
4
Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.α-半乳糖苷酶A-反式激活转录蛋白融合体增强法布里病小鼠心脏和肾脏中的蓄积减少
Mol Med. 2010 May-Jun;16(5-6):216-21. doi: 10.2119/molmed.2009.00163. Epub 2010 Feb 17.
5
Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders.诱导多能干细胞源自溶酶体贮积症的小鼠模型。
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7886-91. doi: 10.1073/pnas.1002758107. Epub 2010 Apr 12.
6
New strategies for enzyme replacement therapy for lysosomal storage diseases.用于溶酶体贮积症的酶替代治疗的新策略。
Rejuvenation Res. 2010 Apr-Jun;13(2-3):229-36. doi: 10.1089/rej.2009.0920.
7
Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models.通过单次脑内注射治疗性慢病毒载体在白质营养不良小鼠模型中对中枢神经系统组织进行广泛的酶学纠正。
Hum Mol Genet. 2010 Jun 1;19(11):2208-27. doi: 10.1093/hmg/ddq099. Epub 2010 Mar 4.
8
Combined hematopoietic and lentiviral gene-transfer therapies in newborn Twitcher mice reveal contemporaneous neurodegeneration and demyelination in Krabbe disease.新生Twitcher小鼠的造血和慢病毒基因转移联合疗法揭示了克拉伯病中同时存在的神经变性和脱髓鞘。
J Neurosci Res. 2009 Jun;87(8):1748-59. doi: 10.1002/jnr.22006.
9
Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.球三糖神经酰胺可诱导法布里病内皮细胞产生氧化应激并上调细胞黏附分子表达。
Mol Genet Metab. 2008 Nov;95(3):163-8. doi: 10.1016/j.ymgme.2008.06.016. Epub 2008 Aug 15.
10
LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.LIMP-2是溶酶体甘露糖-6-磷酸非依赖性靶向β-葡萄糖脑苷脂酶的受体。
Cell. 2007 Nov 16;131(4):770-83. doi: 10.1016/j.cell.2007.10.018.